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Bacteremia: A Population-Based Study
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1Department of Infectious Diseases, Aalborg University Hospital, Denmark; 2Department of Clinical Epidemiology and 3Department of Clinical Biochemistry, Aarhus University Hospital, Denmark; 
4Institute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University, Düsseldorf, Germany; 5Department of Clinical Medicine, Aalborg University, Denmark; 6Department of Clinical 
Microbiology, Aalborg University Hospital, Denmark; 7Department of Cardiovascular Diseases and 8Division of Infectious Diseases, Mayo Clinic Rochester, Minnesota; 9Aalborg Thrombosis 
Research Unit, Aalborg University, Denmark; 10Department of Cardiology, Aalborg University Hospital, Denmark
Objective: To investigate the influence of acetylsalicylic acid (ASA) use on risk and outcome of community-acquired 
Staphylococcus aureus bacteremia (CA-SAB).
Method: We used population-based medical databases to identify all patients diagnosed in northern Denmark with first-time 
CA-SAB and matched population controls from 2000–2011. Categories for ASA users included current users (new or long-term 
users), former users, and nonusers. The analyses were adjusted for comorbidities, comedication use, and socioeconomic indicators.
Results: We identified 2638 patients with first-time CA-SAB and 26 379 matched population controls. Compared with nonusers, 
the adjusted odds ratio (aOR) for CA-SAB was 1.00 (95% confidence interval [CI], 0.88–1.13) for current users, 1.00 (95% CI, 
0.86–1.16) for former users, 2.04 (95% CI, 1.42–2.94) for new users, and 0.95 (95% CI, 0.84–1.09) for long-term users. Thirty-day 
cumulative mortality was 28.0% among current users compared with 21.6% among nonusers, yielding an adjusted hazard rate ratio 
(aHRR) of 1.02 (95% CI, 0.84–1.25). Compared with nonusers, the aHRR was 1.10 (95% CI, 0.87–1.40) for former users, 0.60 (95% 
CI, 0.29–1.21) for new users, and 1.06 (95% CI, 0.87–1.31) for long-term users. We observed no difference in the risk or outcome of 
CA-SAB with increasing ASA dose or by presence of diseases commonly treated with ASA.
Conclusions: Use of ASA did not seem to influence the risk or outcome of CA-SAB. The apparent increased risk among new 
users may relate to residual confounding from the circumstances underlying ASA treatment initiation. Our finding of no associa-
tion remained robust with increasing ASA dose and across multiple patient subsets.
Key words: acetylsalicylic acid; aspirin; outcome; prognosis; risk; Staphylococcus aureus bacteremia.
INTRODUCTION
Staphylococcus aureus bacteremia (SAB) is a serious infection 
that continues to be associated with considerable morbidity and 
a 30-day mortality of 20%–30% [1, 2]. Acetylsalicylic acid (ASA) 
remains a critically important agent in the secondary preven-
tion of atherosclerotic disease on a global scale [3]. In addition 
to its role in cardiovascular prophylaxis, an increasing number 
of studies have suggested that ASA has a number of effects on 
the immune system, which in turn may influence the risk and 
outcome of SAB. For example, in vitro data suggest that ASA 
mediates a direct antimicrobial effect against staphylococci [4]. 
Moreover, ASA has been shown to exert anti-inflammatory ef-
fects in sepsis [5–7] and, by inhibiting platelet activation, ASA 
may reduce the risk of thromboembolic complications associ-
ated with SAB [8, 9].
Nevertheless, there is a paucity of clinical data on the associa-
tion between ASA use and SAB, and, to the best our knowledge, 
only 2 previous studies have elucidated the influence of ASA 
use on the risk and outcome of SAB, respectively [10, 11]. As 
SAB is associated with an adverse clinical impact on patients 
and substantial healthcare costs, any association with use of a 
widespread and inexpensive treatment, such as ASA, could have 
valuable potential for clinical care. We therefore conducted a 
combined population-based case-control and cohort study to 
investigate whether ASA treatment influenced the risk and the 
outcome of community-acquired (CA-)SAB when comparing 
users with nonusers. In addition, we examined whether the risk 
and outcome of CA-SAB differed by intensity of ASA use, by 
selected chronic medical conditions commonly treated with 
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ASA, by duration of ASA use, and by age, gender, and comor-
bidity level.
METHODS
Design and Setting
We conducted this combined case-control and cohort study in 
northern Denmark (catchment population ~ 1.8 million inhab-
itants) between January 1, 2000, and December 31, 2011, using 
population-based medical registries with routinely recorded 
data. Denmark has a tax-supported healthcare system pro-
viding free medical care and partial reimbursement for the costs 
of most prescribed medications, including ASA. The unique 
10-digit identification number assigned to all Danish citizens 
upon birth or immigration (the civil registration number) al-
lows unambiguous electronic linkage of patient records across 
the data sources [12]. According to Danish legislation, indi-
vidual consent is not required for registry-based studies. The 
project was approved by the Danish Data Protection Agency 
(record no. 2012-41-0942).
Patients With S. aureus Bacteremia
We identified patients hospitalized with CA-SAB in the data-
bases of the departments of clinical microbiology within the 
catchment area from 1995 onwards (information on blood 
culture practice and susceptibility testing is provided in the 
Supplementary Appendix 1). Eligible patients were defined as 
patients aged 15 years or older with 1 or more positive blood 
cultures in which S. aureus was the only isolate. Recurrence of 
SAB is strongly associated with outcome [13]. Therefore, we re-
stricted the study to patients with first-time CA-SAB, defined as 
no previous SAB diagnosis within at least 5 years of the current 
hospitalization. If the first positive blood culture was obtained 
within 2  days of admission, SAB was defined as community-
acquired. If the first positive blood culture was obtained >2 days 
after admission, the infection was considered hospital-acquired 
and the patient was excluded. Patients with CA-SAB and health-
care contacts within 30 days of the current hospitalization were 
classified as having healthcare-associated SAB (HCA-SAB) if 
1 or more of the following criteria were fulfilled: hospital ad-
mission, contacts to hospital outpatient surgical clinics, or con-
tacts to clinics of oncology, hematology, or nephrology [14]. We 
retrieved information on recent healthcare contacts from the 
Danish National Patient Registry (DNPR), which has tracked 
all admissions to Danish hospitals since 1977 and all visits to 
hospital outpatient clinics since 1995. The DNPR records log 
the dates of hospital admission and discharge, discharge diag-
noses assigned by treating physicians, and data on surgical pro-
cedures [15].
Selection of Population Controls and Outcome
The Danish Civil Registration System (DCRS), which is up-
dated daily, tracks age, gender, residence, marital status, and 
vital status for all Danish residents [12]. Using this registry, 
we randomly selected 10 population controls on the date the 
first positive blood culture was drawn and matched them to the 
CA-SAB cases by age, gender, and residence (northern Denmark 
region or central Denmark region). All controls were assigned 
an index date identical to the CA-SAB admission date for the 
matched case. The risk set sampling technique was applied [16], 
requiring that the population controls were alive and at risk of 
a first hospitalization with SAB on the date the corresponding 
case was admitted. In the cohort study, data on all-cause 30-day 
mortality were collected from the DCRS [12].
Use of Acetylsalicylic Acid
The Aarhus University Prescription Database (AUPD) contains 
data on all prescriptions dispensed in northern Denmark since 
1998 [17]. Information in the AUPD includes the name and 
Anatomical Therapeutic Classification (ATC) code of the drug, 
date of dispensing, dosage, and number of packages dispensed. 
Using this database, we identified all prescriptions filled for 
ASA by the study participants prior to the SAB admission date. 
(ATC codes are provided in the Supplementary Appendix 2). 
We applied previously used methods [18] to define current 
users as patients who had filled a prescription for ASA within 
125 days before the SAB admission date. In order to account for 
variations in duration of ASA use, the current user group was 
further subcategorized into new users, who filled their first-ever 
prescription within 125 days of their SAB admission date, and 
long-term users, who previously had redeemed a prescription 
for ASA. Former users were defined as patients whose last pre-
scription redemption was more than 125 days predating their 
SAB admission date. Nonusers (ie, patients with no filled pre-
scription for ASA recorded in the AUPD) served as the refer-
ence group for all comparisons. Furthermore, we defined the 
intensity of ASA use among current and former users as the 
number of pills filled multiplied by drug dosage in milligrams 
divided by the total duration of use in days. Duration of ASA 
use was determined by counting the number of days between 
the dates of the first and last prescription redemption before the 
SAB admission date.
Demographic Data, Coexisting Morbidities, and Comedications
The DCRS [12] provided data on gender, age, and marital 
status. We used the DNPR to identify all inpatient and outpa-
tient diagnoses of comorbidities recorded up to 10 years before 
(but not on) the index date, and a Charlson Comorbidity Index 
(CCI) was computed for all patients and controls. The CCI as-
signs 1 to 6 points to 19 major disease categories and previously 
has been validated for use with hospital discharge registry data 
to predict mortality, including mortality after SAB [19, 20]. 
An aggregate score was calculated for each study participant, 
who then were classified as having a low (score = 0), interme-
diate (score = 1–2), or a high comorbidity level (score > 2). The 
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DNPR [15] also provided information on diagnoses of hyper-
tension, alcohol-related conditions, and dialysis within 30 days 
of the index admission, which are not included in the CCI. 
Finally, we obtained data from the AUPD [17] on concomitant 
use of (1) vitamin K antagonists, thrombocyte inhibitors, an-
giotensin converting enzyme (ACE) inhibitors, beta blockers, 
and calcium channel blockers (any previous use); (2) statins, 
NSAIDs, systemic glucocorticoids, antineoplastic, or immuno-
suppressive medication (used within 90 days of the index date); 
and (3) antibiotics (used within 30 days of the index date). All 
relevant diagnostic codes and ATC codes are provided in the 
Supplementary Appendix 2.
Statistical Analysis
In the case-control study, characteristics of cases and controls 
were first described in a contingency table. Next, conditional 
logistic regression was applied to compute crude and ad-
justed odds ratios (ORs) with corresponding 95% confidence 
intervals (CIs) as a measure of the relative risks of CA-SAB 
among current, new, long-term, and former ASA users com-
pared with nonusers. We adjusted for conditions included in 
the CCI score, marital status, alcohol-related conditions, treat-
ment with statins, glucocorticoids, antineoplastic agents, or 
immunomodulating agents (within 90 days of the index date), 
and any previous use of other thrombocyte inhibitors and vi-
tamin K antagonists. These potential confounding factors were 
carefully selected a priori based on the existing knowledge on 
risk and prognostic factors for CA-SAB.
In the cohort study, we followed patients from the date on 
which the patient´s first positive blood culture was drawn, 
until death, migration, or for 30  days, whichever came first. 
Characteristics of ASA users and nonusers were summarized 
in a contingency table, and a Cox proportional hazards model 
was used to compare 30-day cumulative mortality rates among 
ASA users and nonusers, including estimation of hazard ratios 
of death with 95% CIs. We adjusted for age, gender, CCI score, 
hypertension, alcohol-related conditions, marital status, use of 
statins or NSAIDs within 90  days of the index date, any pre-
vious use of other thrombocyte inhibitors, vitamin K antagon-
ists, beta blockers, ACE inhibitors or calcium channel blockers, 
and use of antibiotics within 30 days of the index date.
In order to examine a potential dose-response relation be-
tween ASA use and CA-SAB, we stratified the analyses of risk 
and outcome according to intensity of ASA use, categorized 
as ≤75  mg/day, >75–150  mg/day, and >150  mg/day. We also 
examined risk and outcome of CA-SAB according to presence 
of selected chronic diseases associated with ASA use (previous 
myocardial infarction, chronic heart failure, peripheral arterial 
disease, chronic kidney disease, and diabetes).
To ascertain whether the potential association between ASA 
use and CA-SAB differed among various subsets of patients, we 
assessed the risk and outcome of CA-SAB according to duration 
of ASA use (categorized as <365  days, 365–1094  days, and 
≥1095  days), and by age, gender, and CCI score. In addition, 
to investigate the potential influence of variations in exposure 
definitions, we repeated the analyses of risk and outcome using 
alternate definitions of current ASA use (prescription redemp-
tion within 60, 90, or 180 days). The assumption of proportional 
hazards in the Cox models was assessed graphically using log-
minus-log plots and found appropriate. All statistical analyses 
were performed using Stata 11.2 for Windows (Stata Corp, 
College Station, TX).
RESULTS
Case-Control Study of the Risk of Community-Acquired S.  aureus 
Bacteremia
Characteristics of cases and controls are shown in Table 1. 
Between 2000 and 2011, we identified 2 638 patients with in-
cident CA-SAB and 26 379 population controls, of which 760 
(28.8%) and 5  308 (20.1%) were current ASA users, respec-
tively. Among patients with CA-SAB, 42% had recent health 
care system contacts (HCA-SAB). Methicillin-resistant S.  au-
reus (MRSA) infections were rare during the study period 
(0.5%). The median age of the study participants was 69 years 
(interquartile range [IQR], 56–79  years) and 61% were men. 
Compared with controls, patients with CA-SAB used more 
medications prior to the index date and had more comorbidity, 
including a history of myocardial infarction (8.3% vs 3.9%), 
diabetes (18.1% vs 4.6%), and chronic kidney disease (16.5% 
vs 1.0%).
The unadjusted OR associating current ASA use with 
CA-SAB risk was 2.05 (95% CI, 1.85–2.28). Adjustment for 
potential confounders reduced the OR to 1.00 (95% CI, 0.88–
1.13), mainly driven by the influence of coexisting morbidities. 
Compared with nonusers, the adjusted OR was 1.00 (95% CI, 
0.86–1.16) for former users, 2.04 (95% CI, 1.42–2.94) for new 
users, and 0.95 (95% CI, 0.84–1.09) for long-term users (Table 
2). We observed no notable difference in risk estimates for cases 
with and without recent healthcare system contacts (data not 
shown).
Cohort Study on the Outcome of Community-Acquired S. aureus Bacteremia
Table 3 presents characteristics of ASA users and nonusers 
in the cohort study. Of the 2  638 patients with CA-SAB, 760 
(28.8%) were current users, 361 (13.7%) were former users, and 
1 517 (57.5%) were nonusers. ASA users tended to be older than 
nonusers and had more coexisting morbidity, including a his-
tory of myocardial infarction (20.7% vs 0.7%), peripheral ar-
terial disease (24.0% vs 4.0%), chronic heart failure (26.3% vs 
4.8%), and chronic kidney disease (24.6% vs 10.6%). In addi-
tion, concomitant use of other types of medication was more 
common among ASA users than among nonusers.
Thirty-day cumulative mortality was 28.0% among cur-
rent ASA users versus 21.6% among nonusers. This yielded 
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an unadjusted HRR of 1.37 (95% CI, 1.15–1.62) and an ad-
justed HRR of 1.02 (95% CI, 0.84–1.25) (Table 4). Compared 
with nonusers, the adjusted HRR was 1.10 (95% CI, 0.87–1.40) 
for former users, 0.60 (95% CI, 0.29–1.21) for new users, and 
1.06 (0.87–1.31) for long-term users. Restricting the analyses 
to patients with and to patients without recent healthcare con-
tacts did not materially influence the risk estimates (data not 
shown).
Additional Analyses
We observed no noteworthy difference in the risk or outcome 
of CA-SAB with successive increases in ASA dose (Table 5), nor 
did we see a clear association between selected diseases treated 
with ASA and CA-SAB risk or outcome (Table 6). Similarly, we 
found no consistent pattern or notable difference in risk or prog-
nosis according to duration of ASA use (Supplementary Table 
1) or according to age, gender, or CCI level (Supplementary 
Table 1. Case-Control Study: Characteristics of Cases With Incident Community-Acquired Staphylococcus aureus Bacteremia and Population Controls 
in Northern Denmark 2000–2011
Characteristics Cases n (%) Controls n (%)
Numbers (%) 2638 (9.1) 26 379 (90.9)
Acetylsalicylic acid use   
 Nonuse 1517 (57.5) 18 606 (70.5)
 Former use 361 (13.7) 2465 (9.3)
 Current use 760 (28.8) 5308 (20.1)
  New use 56 (2.1) 216 (0.8)
  Long-term use 704 (26.7) 5092 (19.3)
Age   
 ≥15–39 years 233 (8.8) 2 340 (8.9)
 40–59 years 605 (22.9) 6009 (22.8)
 60–79 years 1182 (44.8) 11 838 (44.9)
 ≥80 years 618 (23.4) 6192 (23.5)
Gender   
 Men 1616 (61.3) 16 159 (61.3)
 Women 1022 (38.7) 10 220 (38.7)
Selected underlying conditions   
 Previous myocardial infarction 220 (8.3) 1037 (3.9)
 Peripheral arterial disease 328 (12.4) 889 (3.4)
 Chronic heart failure 348 (13.2) 960 (3.6)
 Chronic kidney disease 435 (16.5) 273 (1.0)
 Diabetes 477 (18.1) 1212 (4.6)
 Hypertension 651 (24.7) 3016 (11.4)
 Moderate to severe liver disease 58 (2.2) 32 (0.1)
 Chronic pulmonary disease 368 (14.0) 1515 (5.7)
 Any solid cancer 655 (24.8) 1928 (7.3)
 Alcohol-related conditions 235 (8.9) 398 (1.5)
 Dialysis within 30 days of the index date 251 (9.5) 21 (0.1)
Charlson Comorbidity Index score   
 Low (0) 725 (27.5) 18 539 (70.3)
 Intermediate (1–2) 941 (35.7) 6215 (23.6)
 High (>2) 972 (36.9) 1625 (6.2)
Medication use   
 ACE inhibitorsa 1086 (41.2) 6768 (25.7)
 Beta blockersa 1035 (39.2) 6470 (24.5)
 Calcium channel blockersa 890 (33.7) 5488 (20.8)
 Vitamin K antagonistsa 429 (16.3) 1674 (6.4)
 Other thrombocyte inhibitorsa 242 (9.2) 1493 (5.7)
 Statinsb 368 (14.0) 3221 (12.2)
 NSAIDsb 584 (22.1) 2662 (10.1)
 Systemic glucocorticoidsb 379 (14.4) 827 (3.1)
 Immunomodulating agentsb 40 (1.5) 128 (0.5)
 Antibiotic treatmentc 536 (20.3) 1252 (4.8)
Abbreviations: ACE, angiotensin-converting enzyme; NSAIDs, nonsteroidal anti-inflammatory drugs.
aAny previous use prior to the index date. 
bAny previous use within 90 days of the index date.
cAny use within 30 days of the index date.
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Table 2.   Case-Control Study: Crude and Adjusted Odds Ratios for Incident Community-Acquired Staphylococcus aureus Bacteremia Associated With 
Use of Acetylsalicylic Acid
Characteristics Cases n (%) Controls n (%) Unadjusted OR (95% CI) Adjusted OR a (95% CI)
ASA use     
 Nonuse 1517 (57.5) 18 606 (70.5) 1.0 (ref.) 1.0 (ref.)
 Former use 361 (13.7) 2465 (9.3) 2.08 (1.83–2.37) 1.00 (0.86–1.16)
 Current use 760 (28.8) 5308 (20.1) 2.05 (1.85–2.28) 1.00 (0.88–1.13)
  New use 56 (2.1) 216 (0.8) 3.63 (2.68–4.90) 2.04 (1.42–2.94)
  Long-term use 704 (26.7) 5092 (19.3) 1.98 (1.78–2.20) 0.95 (0.84–1.09)
Abbreviations: ASA, acetylsalicylic acid; CI, confidence interval; OR, odds ratio; ref., reference.
aAdjusted for conditions included in the Charlson Comorbidity Index, marital status, alcohol-related conditions, use of statins, glucocorticoids or treatment with antineoplastic or 
immunomodulating agents (within 90 days of the index date), and any previous use of other thrombocyte inhibitors and vitamin K antagonists.
Table 3. Cohort Study: Characteristics of 2638 Patients Hospitalized With Incident Community-Acquired Staphylococcus aureus Bacteremia in Northern 
Denmark (2000–2011) According to Acetylsalicylic Acid Use
Characteristics Current use New use Long-term use Former use Nonuse
Numbers (%) 760 (28.8) 56 (2.1) 704 (26.7) 361 (13.7) 1517 (57.5)
Age      
 ≥15–39 years 9 (1.2) 1 (1.8) 8 (1.1) 7 (1.9) 217 (14.3)
 40–59 years 93 (12.2) 11 (19.6) 82 (11.7) 42 (11.6) 470 (30.9)
 60–79 years 379 (49.9) 32 (57.1) 347 (49.3) 200 (55.4) 603 (39.8)
 ≥80 years 279 (36.7) 12 (21.4) 267 (37.9) 112 (31.0) 227 (15.0)
Gender      
 Men 490 (64.5) 36 (64.3) 454 (64.5) 220 (60.9) 906 (59.7)
 Women 270 (35.5) 20 (35.7) 250 (35.5) 141 (39.1) 611 (40.3)
Selected underlying conditions      
 Previous myocardial infarction 157 (20.7) 7 (12.5) 150 (21.3) 52 (14.4) 11 (0.7)
 Peripheral arterial disease 182 (24.0) 6 (10.7) 176 (25.0) 85 (23.6) 61 (4.0)
 Chronic heart failure 200 (26.3) 7 (12.5) 193 (27.4) 75 (20.8) 73 (4.8)
 Chronic kidney disease 187 (24.6) 15 (26.8) 172 (24.4) 88 (24.4) 160 (10.6)
 Diabetes 226 (29.7) 11 (19.6) 215 (30.5) 80 (22.2) 171 (11.3)
 Hypertension 328 (43.2) 14 (25.0) 314 (44.6) 137 (38.0) 186 (12.3)
 Moderate to severe liver disease 6 (0.8) 1 (1.8) 5 (0.7) 7 (1.9) 45 (3.0)
 Chronic pulmonary disease 137 (18.0) 10 (17.9) 127 (18.0) 60 (16.6) 171 (11.3)
 Any solid cancer 150 (19.7) 16 (28.6) 134 (19.0) 96 (26.6) 409 (27.0)
 Alcohol-related conditions 41 (5.4) 3 (5.4) 38 (5.4) 29 (8.0) 165 (10.9)
 Dialysis within 30 days of the admission 111 (14.6) 9 (16.1) 102 (14.5) 46 (12.7) 94 (6.2)
Charlson Comorbidity Index score      
 Low (0) 94 (12.4) 11 (19.6) 83 (11.8) 55 (15.2) 576 (38.0)
 Intermediate (1–2) 283 (37.2) 20 (35.7) 263 (37.4) 124 (34.4) 534 (35.2)
 High (>2) 383 (50.4) 25 (44.6) 358 (50.9) 182 (50.4) 407 (26.8)
Medication use      
 ACE inhibitorsa 497 (65.4) 27 (48.2) 470 (66.8) 207 (57.3) 382 (25.2)
 Beta blockersa 460 (60.5) 26 (46.4) 434 (61.7) 208 (57.6) 367 (24.2)
 Calcium channel blockersa 412 (54.2) 20 (35.7) 392 (55.7) 199 (55.1) 279 (18.4)
 Vitamin K antagonistsa 172 (22.6) 7 (12.5) 165 (23.4) 115 (31.9) 142 (9.4)
 Other thrombocyte inhibitorsa 169 (22.2) 7 (12.5) 162 (23.0) 56 (15.5) 17 (1.1)
 Statinsb 230 (30.3) 14 (25.0) 216 (30.7) 69 (19.1) 69 (4.6)
 NSAIDsb 136 (17.9) 12 (21.4) 124 (17.6) 67 (18.6) 381 (25.1)
 Systemic glucocorticoidsb 109 (14.3) 12 (21.4) 97 (13.8) 53 (14.7) 217 (14.3)
 Immunomodulating agentsb 8 (1.1) 1 (1.8) 7 (1.0) 8 (2.2) 24 (1.6)
Antibiotic treatment prior to admissionc 184 (24.2) 12 (21.4) 172 (24.4) 75 (20.8) 277 (18.3)
Abbreviations: ACE, angiotensin-converting enzyme; NSAIDs: nonsteroidal anti-inflammatory drugs.
aAny previous use prior to the date of admission. 
bAny previous use within 90 days of the date of admission. 
cAny previous use within 30 days of the date of admission.
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Table 2). Finally, changing the exposure window used to de-
fine current ASA use from 125 days to 60, 90, and 180 days did 
not markedly affect our results (Supplementary Tables 3 and 4, 
respectively).
DISCUSSION
In this combined case-control and cohort study, persons who 
used ASA did not experience a decreased risk of CA-SAB or 
a difference in 30-day CA-SAB all-cause mortality, compared 
with nonusers. We observed no notable differences in the risk 
or outcome of CA-SAB with increasing intensity of ASA use, 
and our estimates remained consistent across subgroups with 
various diseases often treated with ASA. As well, no substantial 
differences in risk or prognosis of CA-SAB were found by dura-
tion of ASA use, age, gender, or CCI level.
To the best of our knowledge, only 1 previous study has spe-
cifically investigated the association between ASA use and SAB 
risk. In a US historical cohort study of 872 patients receiving 
hemodialysis, Sedlacek et al reported a lower rate of catheter-
associated SAB in patients treated with ASA versus those not 
treated with ASA (0.17 vs 0.34 events per patient-catheter-year) 
[10]. The association was dose-dependent and was observed 
most often with the 325  mg dose. However, a Canadian 
population-based case-control study of 449 patients and 4 156 
controls receiving hemodialysis reported no association be-
tween ASA use and risk of vascular access-related infections 
and sepsis (OR, 1.03; 95% CI, 0.82–1.28), which remained un-
changed with increasing ASA dose [21]. Also in support of our 
findings, a recent US historical cohort study of 30 239 patients 
reported an aHRR of 0.99 (95% CI, 0.88–1.12) for hospitaliza-
tion with sepsis associated with ASA use [22].
Regarding prognosis, a Swiss single-center propensity score-
matched cohort study of 314 patients with SAB examined the 
influence of ASA use on 30-day all-cause mortality, employing 
patients with E. coli bacteremia as an additional control group 
[11]. The investigators found that ASA use was associated with 
decreased mortality among patients with SAB (aHRR, 0.38; 95% 
CI, 0.21–0.69); however, the association reduced towards the 
null among patients with E.coli bacteremia (aHRR, 0.78; 95% 
CI, 0.40–1.55). To our knowledge, this represents the only pre-
vious study to focus specifically on SAB, still a number of prior 
studies have ascertained the association between ASA use and 
sepsis outcome with conflicting results. An Australian historical 
propensity score-matched cohort study examining 7 945 inten-
sive care unit admissions, reported an absolute risk difference of 
Table 5. Risk and Outcome of Incident Community-Acquired Staphylococcus aureus Bacteremia According to Intensity of Acetylsalicylic Acid Treatment
Characteristics Risk of Incident CA-SAB 30-day Mortality After Incident CA-SAB 
 Unadjusted OR (95% CI) Adjusted OR (95% CI) a Unadjusted HRR (95% CI) Adjusted HRR (95% CI)b
Nonuse 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
Former use     
 ≤75 mg/day 1.89 (1.63–2.20) 0.95 (0.90–1.13) 1.54 (1.20–1.97) 1.13 (0.87–1.48)
 >75–150 mg/day 2.71 (2.16–3.40) 1.15 (0.89–1.49) 1.44 (0.98–2.10) 1.05 (0.71–1.56)
 >150 mg/day 2.41 (1.22–4.36) 1.12 (0.58–2.17) 1.94 (0.80–4.70) 0.96 (0.39–2.36)
Current use     
 ≤75 mg/day 2.19 (1.84–2.61) 1.09 (0.89–1.34) 1.37 (1.03–1.84) 1.12 (0.81–1.54)
 >75–150 mg/day 1.99 (1.76–2.25) 0.98 (0.84–1.14) 1.40 (1.14–1.71) 1.07 (0.84–1.36)
 >150 mg/day 1.85 (1.50–2.28) 0.93 (0.73–1.18) 1.23 (0.85–1.79) 1.07 (0.73–1.58)
Abbreviations: CA-SAB, community-acquired Staphylococcus aureus bacteremia; CI, confidence interval; HRR, hazard rate ratio; OR, odds ratio. 
aAdjusted for conditions included in the Charlson Comorbidity Index; marital status; alcohol-related conditions; use of statins, glucocorticoids with antineoplastic, or immunomodulating 
agents (within 90 days of the index date); and any previous use of other thrombocyte inhibitors and vitamin K antagonists.
bAdjusted for age, gender, Charlson Comorbidity Index score, hypertension, alcohol-related conditions, marital status, use of statins, NSAIDs (within 90 days of the index date), any previous 
use of other thrombocyte inhibitors, vitamin K antagonists, beta blockers, ACE inhibitors, calcium channel blockers, and use of antibiotics within 30 days of the admission.
Table 4. Cohort Study: Unadjusted and Adjusted 30-day Mortality in Patients With Community-Acquired Incident Staphylococcus aureus Bacteremia 
According to Acetylsalicylic Acid Use
Characteristics n 30-day Mortality (95% CI) HRR (95% CI) aHRRa (95% CI)
 Nonuse 1517 21.6 (19.6–23.8) 1.00 (ref.) 1.00 (ref.)
 Former use 361 30.8 (26.3–35.8) 1.53 (1.23–1.89) 1.10 (0.87–1.40)
 Current use 760 28.0 (25.0–31.4) 1.37 (1.15–1.62) 1.02 (0.84–1.25)
  New use 56 14.3 (7.4–26.5) 0.65 (0.32–1.30) 0.60 (0.29–1.21)
  Long-term use 704 29.12 (25.9–32.6) 1.43 (1.20–1.70) 1.06 (0.87–1.31)
Abbreviations: aHRR, adjusted hazard rate ratio; CI, confidence interval; HRR, hazard rate ratio.
aAdjusted for age, gender, Charlson Comorbidity Index score; hypertension; alcohol-related conditions; marital status; use of statins, NSAIDs (within 90 days of the index date), and any 
previous use of other thrombocyte inhibitors; vitamin K antagonists; beta blockers; ACE inhibitors; calcium channel blockers, and use of antibiotics within 30 days of the admission.
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-14.8% (95% CI, -18.9% to -8.6%) for sepsis-related in-hospital 
mortality, comparing patients treated with ASA versus those 
not treated [23]. A  German single-center historical cohort 
study of 886 patients who were admitted with sepsis to a sur-
gical intensive care unit reported a decreased risk of in-hospital 
death associated with ASA use (aOR, 0.56; 95% CI, 0.37–0.84) 
[24]. Furthermore, a US historical propensity score-matched 
cohort study of 651 patients with sepsis or septic shock being 
treated in an intensive care unit reported an adjusted odds ratio 
of in-hospital death of 0.73 (95% CI, 0.46–1.16) associated with 
chronic antiplatelet treatment, including ASA [25]. In line with 
our results, a Dutch prospective propensity score-matched co-
hort study of 972 patients admitted with sepsis to an intensive 
care unit found no association between chronic antiplatelet 
therapy (>95% received ASA) and clinical presentation or 
30-day all-cause mortality (adjusted hazard ratio, 1.21; 95% CI, 
0.79–1.84) [26].
A number of limitations should be taken into account 
interpreting these earlier studies. In contrast to our population-
based setting, several previous studies were conducted in ter-
tiary single centers focusing on selected groups of patients (eg, 
patients receiving dialysis) [10, 23, 24], which increases the risk 
of selection bias. The majority of previous studies did not ac-
cess microbiological data to identify infections, including sepsis 
[21–23]. Thus, misclassification cannot be entirely ruled out, 
and some lacked complete follow-up [22, 25]. Moreover, in-
formation on ASA exposure use was in some cases collected ex-
clusively from medical charts that may be incomplete [10, 25], 
and variations in the duration of ASA use were not taken into 
account [10, 21, 24, 25].
The mechanisms underlying our results are not entirely clear. 
It remains possible that the observed lack of association between 
ASA use and CA-SAB risk and prognosis may be explained by 
insufficient ASA dosage. Still, our estimates remained robust 
across all dose categories, and further dose escalations would 
likely be inadvisable due to increased risk of adverse events, in-
cluding gastrointestinal bleeding [27]. Our patient cohort was 
population-based and well-defined. Nevertheless, patients with 
CA-SAB remain inherently heterogeneous in terms of personal 
and genetic background, disease presentation and severity, and 
distribution of the infective foci, which might partly explain the 
lack of impact by ASA therapy. Moreover, most patients in our 
study were over 65 years old and suffered from multiple chronic 
diseases. Thus, the overall risk and outcome of CA-SAB could 
be influenced primarily by the accumulated burden of advanced 
age, comorbidity, and reduced functional status, and less so by 
individual types of drugs, such as ASA.
Surprisingly, our study suggests that new use of ASA is as-
sociated with increased risk of CA-SAB, but with a protective 
impact on outcome. We speculate that in fact these observations 
are not explained by ASA use, but rather by the circumstances 
underlying recent ASA treatment initiation (eg, hospitalization 
due to cardiovascular disease), which influence baseline risk 
and prognosis of CA-SAB. Combined with the limited number 
of new users yielding imprecise estimates, these results warrant 
cautious clinical interpretation.
Our study has several strengths, including its considerable 
size and our unfettered access to routinely recorded clinical data 
at the individual level. The study design allowed us to assess 
ASA use both as a potential risk as well as a prognostic factor 
for CA-SAB. By excluding patients with hospital-acquired SAB, 
we reduced the risk of bias associated with concurrent medical 
conditions and with invasive procedures. We also had detailed 
data on ASA use, and the comprehensive data on ASA prescrip-
tions available from the AUPD eliminated the risk of recall bias.
However, a number of limitations should be considered in 
the interpretation of our results. The study´s population-based 
design ensured capture of all incident CA-SAB cases during the 
study period. Still, we may have missed some cases in which 
the patient was hospitalized outside the study area, was treated 
Table 6. Risk and Outcome of Incident Community-Acquired Staphylococcus aureus Bacteremia According to Selected Diseases Associated With the 
Use of Acetylsalicylic Acid
Characteristics
Risk of Incident CA-SAB 30-day Mortality After Incident CA-SAB 
Adjusted OR (95% CI)a Adjusted HRR (95% CI)b
 Former ASA use Current ASA use Former ASA use Current ASA use
Previous myocardial infarction 1.34 (0.59–3.05) 1.00 (0.46–2.18) 1.11 (0.87–1.43) 1.02 (0.83–1.26)
Chronic heart failure 0.93 (0.60–1.44) 1.04 (0.72–1.51) 1.11 (0.60–2.05) 1.12 (0.67–1.87)
Peripheral arterial disease 1.34 (0.85–2.10) 1.13 (0.75–1.69) 1.02 (0.79–1.33) 1.01 (0.81–1.26)
Chronic kidney disease 1.20 (0.71–2.02) 1.06 (0.69–1.63) 1.21 (0.64–2.28) 0.90 (0.51–1.60)
Diabetes 0.73 (0.50–1.08) 0.77 (0.57–1.04) 1.33 (0.77–2.29) 1.15 (0.72–1.84)
Nonusers served as reference for all comparisons. 
Abbreviations: CA-SAB, community-acquired Staphylococcus aureus bacteremia; CI, confidence interval; HRR, hazard rate ratio; OR, odds ratio. 
aAdjusted for conditions included in the Charlson Comorbidity Index, marital status, alcohol-related conditions, use of statins, glucocorticoids or treatment with antineoplastic or 
immunomodulating agents (within 90 days of the index date), and any previous use of other thrombocyte inhibitors and vitamin K antagonists.
bAdjusted for age, gender, Charlson Comorbidity Index, hypertension, alcohol-related conditions, marital status, use of statins, NSAIDs (within 90 days of the index date), any previous use 
of other thrombocyte inhibitors, vitamin K antagonists, beta blockers, ACE inhibitors, calcium channel blockers, and use of antibiotics within 30 days of the admission.
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with antibiotics prior to admission, or died before blood could 
be cultured. Data on the infective foci were not available and 
this might have influenced our findings if the foci were une-
venly distributed among ASA users and nonusers. Moreover, 
clinical care for patients with CA-SAB may have varied during 
the study period. Yet, we did not have detailed information on 
clinical work-up and in-hospital treatment, which would have 
strengthened the study.
In addition, records of filled prescriptions were used as a proxy 
for actual ASA use, but the AUPD does not include data on ad-
herence. Nevertheless, a close correspondence between general 
practitioner-reported drug use and timing of prescription dis-
pensation was demonstrated in a previous validation study from 
our study area [28]. Moreover, we observed no notable difference 
in effect estimates when the date used to distinguish current and 
former use was changed in a sensitivity analysis. We lacked data 
on ASA treatment during hospitalization and long-term rehabili-
tation facilities, which might have introduced some misclassifica-
tion. As well, in Denmark, ASA is available either by prescription 
from a physician or over-the-counter (OTC), but unfortunately 
we did not have data on OTC use. Still, as the percentage of ASA 
sales based on a prescription increased notably during the study 
period (77% in 2002, 89% in 2006, and 91% in 2011) [29], it is un-
likely that underreporting of ASA treatment notably influenced 
our estimates of risk or prognosis. Along with increasing ASA 
use [30], the incidence of CA-SAB also rose in Denmark during 
the study period [31]. Such changes could be speculated to in-
flate the estimates; still, we find it unlikely that they explain the 
consistent null-findings across risk and prognosis in our study. 
We also lacked detailed information on educational level and 
personal income. Although socioeconomic status may be asso-
ciated with ASA use and risk or prognosis of CA-SAB, we do 
not consider substantial confounding from this factor likely, be-
cause ASA is inexpensive, prescriptions are partially reimbursed, 
and free unlimited access to healthcare is available to all Danish 
residents. Finally, although we included hospital diagnoses of 
alcohol-related conditions, these diagnoses are likely to capture 
only the most severe cases.
In conclusion, use of ASA did not seem to influence the risk 
and prognosis of CA-SAB. The observed increased risk among 
new users may be related to residual confounding from the cir-
cumstances underlying ASA treatment initiation and a limited 
subsample size; cautious interpretation, therefore, is warranted. 
Although our results argue strongly against a beneficial effect 
of ASA on the risk and outcome of CA-SAB, it should be noted 
that previous observational studies have suggested otherwise. 
Hopefully, further clinical studies, including randomized con-
trolled trials [32], will provide further clarification.
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